Aimmune Therapeutics - 48 Year Dividend Yield History | AIMT

Historical dividend payout and yield for Aimmune Therapeutics (AIMT) since 1971. The current TTM dividend payout for Aimmune Therapeutics (AIMT) as of March 15, 2019 is $0.00. The current dividend yield for Aimmune Therapeutics as of March 15, 2019 is 0.00%.
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.459B $0.000B
Aimmune Therapeutics, Inc. is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies. The Company's characterized oral desensitization immunotherapy includes AR101, a product for the treatment of peanut allergy in children and adults which is in clinical trial stage. Aimmune Therapeutics, Inc. is headquartered in Brisbane, California.
Stock Name Country Market Cap PE Ratio
Amgen (AMGN) United States $119.004B 13.27
Gilead Sciences (GILD) United States $83.712B 10.65
Bio-Techne Corp (TECH) United States $7.389B 49.78